Clinical ReportsWeekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB–IIA cervical cancer with risk of recurrenceZhu, Jiahaoa,,*; Lou, Ruia,,*; Ji, Shengjunb,,*; Wu, Ganga; Chen, Qingqingb; Hu, Qunchaoc; Zhao, Yutiana; Cai, Dongyana; Gu, KeaAuthor Information aDepartment of Radiotherapy and Oncology, Affiliated Hospital of Jiangnan University, Wuxi bDepartment of Radiotherapy and Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu cDepartment of Radiation Oncology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, P.R. China *Jiahao Zhu, Rui Lou, and Shengjun Ji contributed equally to the writing of this article. Received 15 May 2020 Revised form accepted 14 October 2020 Correspondence to Ke Gu, MD, PhD, Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, 200 Huihe Road, Wuxi, China, 214062, Tel: +86051088682999; fax: +051085808820; e-mail: [email protected] Anti-Cancer Drugs: February 2021 - Volume 32 - Issue 2 - p 203-209 doi: 10.1097/CAD.0000000000001018 Buy Metrics Abstract Weekly and triweekly cisplatin-alone concomitant chemoradiotherapy regimens after radical surgery were compared in stages IB–IIA cervical cancer with intermediate- or high-risk factors to identify the better therapeutic regimen. We retrospectively analyzed patients with stages IB–IIA cervical cancer who received radical hysterectomy followed by concurrent adjuvant chemoradiotherapy to compare the efficiency between weekly and triweekly regimen groups. We evaluated between-group differences in survival, recurrence, compliance, and adverse effects. A total of 217 patients were included in this study (triweekly group vs. weekly group; 97 vs. 120). The mean follow-up was 47.2 months. The 5-year disease-free survival (DFS) was 84.4% or 76.5% for patients treated with triweekly cisplatin chemotherapy or the weekly regimen, respectively (P = 0.110). The 5-year overall survival (OS) was 82.4 and 78.6% for the same treatment groups, respectively (P = 0.540). The DFS of the patients with pelvic lymph node metastasis were marginally better in triweekly regimen group compared with the weekly group (P = 0.031). Grades 3–4 leukopenia was significantly more common in the triweekly group (P = 0.028). The weekly cisplatin chemotherapy group experienced the same therapeutic effect as the triweekly cisplatin-alone chemotherapy group but with less toxicity. However, triweekly cisplatin regimen reduced the recurrence in patients with pelvic lymph node metastasis. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.